Company profile
Kailera Therapeutics
Obesity/metabolic small-molecule & peptide GLP-1 portfolio (licensed from Hengrui)
Share price · KLRA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorSmall molecule | ObesityType 2 DiabetesHypertensionHeart Failure | |
| Phase 3 | GLP-1/GIP receptor (dual)Peptide | ObesityType 2 DiabetesHeart FailureAtherosclerotic Cardiovascular Disease |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.